Specialists Eye Gazyva as a New Option for Lupus Nephritis, but ACR Guidelines Favor Benlysta and Lupkynis for Upfront Use, According to Spherix Global Insights
The ACR’s updated lupus nephritis treatment guidelines emphasize triple therapy regimens anchored by Benlysta or a calcineurin inhibitor, while Gazyva’s potential role in the evolving landscape remains to be established as the field continues to advance. Exton, PA., April 30, 2025 – The American College of Rheumatology’s (ACR) newly updated treatment guidelines for lupus nephritis […]
Excitement Builds for Tremfya Among US Gastroenterologists as the FDA Approves its Expansion into Crohn’s Disease, Suggesting the Brand May Impact Competitor Skyrizi’s Growth
Gastroenterologists are enthusiastic about Tremfya’s subcutaneous induction option in Crohn’s disease, a key potential brand differentiator, according to Spherix Global Insights. EXTON, PA., March 28, 2025 – The treatment landscape for Crohn’s disease continues to evolve with the recent FDA approval of Johnson and Johnson Innovative Medicine’s Tremfya (guselkumab). This significant milestone makes Tremfya the […]
US Rheumatologists Report Heightened Interest in Sotyktu for the Treatment of Psoriatic Arthritis Post Positive Trial Results, According to Spherix Global Insights
While interest in BMS’s pipeline asset is strong, some prescribers are underwhelmed by ACR20 endpoint. EXTON, PA, March 27, 2025 – In late 2024, Bristol Myers Squibb announced positive topline results from its pivotal Phase 3 trials, POETYK PsA-1 and PsA-2, evaluating Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met their […]
US Hematologists Show Cautious Optimism as Data Reveal Early Adoption Trends for Hympavzi (Pfizer) and Alhemo (Novo Nordisk) in Hemophilia A and B, According to Spherix Global Insights
Hematologists remain undecided on the long-term role of newly launched hemophilia therapies, particularly as the industry awaits word on Sanofi’s fitusiran by the end of March. Exton, PA, March 26, 2025 – The hemophilia treatment landscape is rapidly evolving, with newly launched therapies and gene therapies joining factor replacement therapies, Hemlibra, and Altuviiio to create […]
Amid Vafseo’s US launch, Akebia plots phase 3 study to grow CKD anemia med’s reach
Vafseo is currently only approved in dialysis patients with chronic kidney disease-related anemia thanks to safety concerns raised by the FDA. Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia Therapeutics’ endgame remains focused on pushing the therapy into a wider pool of patients both […]
BMS’ Sotyktu Notches Phase III Win in Psoriatic Arthritis
In the plaque psoriasis arena, Sotyktu is facing off against Amgen’s Otezla and is facing the threat of upcoming competition from Alumis’ investigational TYK2 inhibitor. Bristol Myers Squibb is building up to a label expansion for Sotyktu, with positive late-stage results from the POETYK PsA-2 study pointing to the potential of its TYK2 inhibitor in psoriatic arthritis. 54.2% […]
UCB’s Bimzelx outpacing AbbVie’s Rinvoq, Skyrizi on awareness early in psoriatic arthritis launch: survey
There are signs Bimzelx is affecting the psoriatic arthritis market. UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its psoriatic arthritis (PsA) launch. Yet, the analysis suggests UCB has work to do to turn awareness into uptake. […]
Amid Novo Nordisk’s Win for Ozempic’s Expanded Label to Include Chronic Kidney Disease Benefits, Spherix Global Insights Highlights Nephrologists’ Rising Influence in GLP-1 RA Utilization
Analysis of over 1,000 chronic kidney disease patient charts shows GLP-1 receptor agonist use nearly doubling from 2023 to 2024. Exton, PA., February 4, 2025 –– As chronic kidney disease (CKD) management evolves, new findings from Spherix Global Insights’ annual Patient Chart Dynamix™: CKD Non-Dialysis (US) service reveal a sharp increase in GLP-1 receptor agonist […]
New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights
Currently, many lupus nephritis treating rheumatologists and nephrologists delay initiating triple therapy, with a significant portion deferring a triple therapy regimen until an initial failure. EXTON, PA., January 9, 2025 – At the 2024 American College of Rheumatology (ACR) Convergence, the organization unveiled updated guidelines for the screening, treatment, and management of Lupus Nephritis (LN)—the […]
Uptake of Benlysta, Saphnelo signal ‘exciting time’ for ‘lupologists’
Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights. A top-line data point from the survey suggests that, among patients with SLE currently treated with biologics by the 100 rheumatologist respondents, 62% were receiving belimumab (Benlysta, GlaxoSmithKline) as of […]
